We have shown that compound 1 lowers CSC, CD44+CD24+, and CD44− subpopulations and expression of CD15s in CD44+CD24+ and CD44− cells, showing that it or similar analogues could be developed into new treatments for triple-negative breast cancer. Here, CD44 is linked to triple-negative breast carcinoma.